Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

2seventybio

Explore full profile

Immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment

Cambridge, United StatesFounded 2021Biotech & Life Sciences
Valuation $336M Market cap · 2025
Revenue $38M Latest reported FY

About 2seventybio

2seventy bio is a biotechnology startup dedicated to revolutionizing cancer treatment. The company's name, inspired by the speed of translating human thought into action (270 miles per hour), reflects its commitment to rapidly advancing cancer therapies. 2seventy bio aims to give people more time to enjoy life by developing innovative treatments that outmaneuver cancer.

The company operates in the biotechnology and healthcare market, focusing on discovering and developing new cancer therapies. It combines deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer. This approach allows 2seventy bio to create treatments that can significantly disrupt the current cancer treatment landscape.

2seventy bio serves patients diagnosed with cancer, healthcare providers, and the broader medical community. Its business model revolves around research and development (R&D) of novel cancer therapies, which are then brought to market through clinical trials and regulatory approval processes. The company generates revenue by commercializing these therapies, either by selling them directly or through partnerships and collaborations with other pharmaceutical companies.

In summary, 2seventy bio is a forward-thinking biotech company focused on developing groundbreaking cancer treatments. By leveraging advanced scientific knowledge and innovative approaches, it aims to provide patients with more time to live their lives fully.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2021
Headquarters
Cambridge, United States
Listing
IPO 2021
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later11 investors entered at this stage

  • CaaS Capital Management
  • Cowen Healthcare Investments
  • Casdin Capital
  • 683 Capital
  • RTW Investments
  • EcoR1 Capital
  • Bain Capital Life Sciences
  • Armistice Capital
  • Janus Henderson Investors
  • Boxer Capital
  • Heights Capital Management
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
920 monthly visits
across markets
🇺🇸 United States97.8%
Top 1 markets shown

Patents

Estimated portfolio value
$112M

41 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about 2seventybio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See 2seventybio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.